Role of Intercellular Adhesion Molecule -1 in Acne Vulgaris patients: Effect of Montelukast therapy

• Published in: SVU - International Journal of Medical Sciences
• Main Authors: Soheir Abdel-Hamid *, et all.
• Format: Article
• Language: English
• Published: South Valley University, Faculty of Medicine 2025-01-01
• Subjects: acne vulgaris s.icam-1 montelukast
• Online Access: https://svuijm.journals.ekb.eg/article_415789.html
• ISSN: 2735-427X; 2636-3402

Background: Acne vulgaris (AV) is the most common inflammatory skin condition. It has complicated pathophysiology. Objectives: We compared montelukast therapy on AV patients over a three-month period, assessing serum of soluble intercellular adhesion molecule -1 (sICAM-1) in AV, comparing it to a control group and its relationship to AV severity. Patients and method: 40 AV patients were split into two groups based on Investigator's Global Assessment: group 1 was moderate AV, group 2 was severe AV. (sICAM-1) was measured in AV patients before and after montelukast treatment and compared to the control group (group 3). Results: Moderate AV group outperformed the severe group in clinical improvement: moderate AV: good (55%), excellent (30%), severe AV: good (40%), and excellent (20%). Median s.ICAM-1 level was significantly lower in the control group (1.3 [0.5-3]) compared with both (moderate AV (35.5 [15-45]) (p < 0.001) and severe AV (57 [45-78]) (p < 0.001). After treatment, there was a significant difference between the three groups in the median level of s.ICAM-1 (p < 0.001) i.e., the median level was significantly lower in the control group (1.3 [0.5-3]) compared with (moderate AV (12.5 [6-72]) (p < 0.001) and severe AV (54 [39-72]) (p < 0.001). Treatment side effects were significant with severe AV (p = 0.046) compared with moderate AV. Conclusion: The study revealed that AV patients had significantly higher serum levels ( sICAM-1), an independent predictor of acne severity. Montelukast is a safe, efficient treatment for AV, especially moderate.